Evidence map›Paper›PMID 42007248›Full record

Trial reportBlood neoplasia2026

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Niels Westra, Elena Ropero Cerro, Edwin Schilder, Marjolijn N Lub-de Hooge, Daan J Touw, Jos G W Kosterink, Dana A Chitu, Emanuele Ammatuna, Saskia K Klein, Peter E Westerweel and 9 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Niels WestraDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Elena Ropero CerroDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Edwin SchilderDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Marjolijn N Lub-de HoogeDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Daan J TouwDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Jos G W KosterinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Dana A ChituDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Emanuele AmmatunaDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Saskia K KleinDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Peter E WesterweelDepartment of Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Marloes CuijpersDepartment of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
Marjan CruijsenDepartment of Hematology, Catharine Hospital, Eindhoven, The Netherlands.
Maarten M F CorstenDepartment of Hematology, Meander Medical Center, Amersfoort, The Netherlands.
Canan AlhanDepartment of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Lidwine TickDepartment of Hematology, Maxima Medical Center, Veldhoven, The Netherlands.
Jan Jacob SchuringaDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Gerwin HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Carolien M WoolthuisDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thijs H Oude MunninkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. Cytochrome P450 3A4 (CYP3A4) is the major metabolizing enzyme for venetoclax, and its inhibition can boost venetoclax. In the HOVON 171 phase 2 trial, patients with AML were treated with azacitidine/venetoclax/cobicistat. This 2-stage, open-label, multicenter phase 2 trial included a crossover run-in phase followed by an ongoing extension phase. In cycle 1, patients received standard-dose azacitidine/venetoclax. In cycle 2, cobicistat was added, and venetoclax was reduced to 50 mg. The primary end point was pharmacokinetic equivalence, defined as 90% confidence interval (CI) of geometric mean ratios (GMRs) >0.8 for area under the curve over 24 hours (AUC

Identifiers

PMID42007248
PMCPMC13091438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.